Moxibustion for Knee osteoarthritis

Moxibustion for knee osteoarthritis: a multi-centre randomized controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CRIS

Registry ID

KCT0000130

Enrollment

212

Registered

2011-06-28

Start date

2011-07-01

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : Treatment group will receive moxibustion treatment on the affected knee(s) at six standard acupuncture points (ST36, ST35, ST34, SP9, Ex-LE04 and SP10) plus up to two points of ‘ashi’

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosed as idiopathic knee osteoarthritis according to the clinical guideline of American college of Rheumatology a. Currently have pain at one or both knee b. Have at least 3 symptoms among the 6 conditions as follows: 1) Aged from 50 to 70 years old 2) Have morning stiffness within 30 minutes 3) Have Crepitus 4) Have Bony tenderness 5) Have Bony enlargement 6) No palpable warmth 2. Have average daily pain over 40 points (0 to 100 point scale) 3. Agreed with written informed consent

Exclusion criteria

Exclusion criteria: 1. Current or past history of inflammatory disease including rheumatoid arthritis 2. Cancer 3. Traumatic injury which might be related to current knee pain 4. Autoimmune disease 5. Significant deformity of knee joints 6. Knee replacement surgery on affected knee 7. Knee arthroscopy within 2 years 8. Steroid injection in knee joints within 3 months 9. Viscosupplement injections in knee joints within 6 months 10. Joint fluid injection within 6 months 11. received acupuncture, moxibustion, cupping or herbal medicine within 4 weeks 12. Uncontrolled hypertension 13. Diabetes mellitus requiring insulin injection 14. life-threatening cardiovascular or neurological events within one year 15. Chronic respiratory disease 16. Hemorrhagic disorder 17. Alcohol or drug addition 18. Active infectious disease including tuberculosis 19. Keloidosis

Design outcomes

Secondary

Measure	Time frame
K-WOMAC subscale (pain, stiffness, function);The Short-Form 36 Health Survey (SF-36);Beck Depression Inventory (BDI);Physical Performance Test;Patient Global Assessment;Pain Numeric Rating Scale (NRS);C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR);Cost-effectiveness analysis;Qualititive study	—

Primary

Measure	Time frame
Korean Western Ontario and McMaster Universities Questionnaire (K-WOMAC) Global score	—

Countries

Korea, Republic of

Contacts

Public ContactTae-Hun Kim

Korea Institute of Oriental Medicine

Outcome results